GB
Gunther Birznieks
SVP, Business Development

Gunther Birznieks insider trades: Vanda Pharmaceuticals (VNDA) stock sales

SVP, Business Development, Vanda Pharmaceuticals Last trade Mar 2, 2026 20 Form 4 filings
$351K
Sold, last 12 months
1 sale
$0
Bought, last 12 months
0 buys
11
Open-market trades
since 2018
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Gunther reports to the SEC

Open-market buys and sales

11 trades reported on SEC Form 4, newest first

DateStockTypeValue
Mar 2, 2026VNDA↓ Sell$351K
Mar 5, 2024VNDA↓ Sell$73K
Mar 3, 2023VNDA↓ Sell$105K
Mar 2, 2022VNDA↓ Sell$175K
Mar 2, 2021VNDA↓ Sell$374K
Mar 3, 2020VNDA↓ Sell$182K
Jan 2, 2020VNDA↓ Sell$64K
Mar 4, 2019VNDA↓ Sell$250K
Jan 3, 2019VNDA↓ Sell$160K
Mar 1, 2018VNDA↓ Sell$160K
Jan 2, 2018VNDA↓ Sell$131K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other VNDA insiders

Open-market trades in the last 12 months

About Gunther Birznieks's insider trades

Gunther Birznieks is SVP, Business Development at Vanda Pharmaceuticals (VNDA). Since Jan 2, 2018, Gunther has reported no open-market purchases and 11 sales worth $2.0M on SEC Form 4. In the last 12 months: 1 sale ($351K).

Their filings also include grants and awards (9 filings), shares withheld for taxes (1 filing), option exercises (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every VNDA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.